Kexing Zhongwei Biotechnology

Beijing Kexing Zhongwei Biotechnology, also known as Sinovac Life Sciences, is a prominent Chinese biopharmaceutical company and a key subsidiary of Sinovac Biotech. The company specializes in the research, development, and large-scale manufacturing of vaccines to protect against infectious diseases. It gained international recognition for the development of CoronaVac, an inactivated COVID-19 vaccine that received Emergency Use Listing from the World Health Organization and was distributed to over 50 countries. In addition to its COVID-19 efforts, the company produces a robust portfolio of vaccines for hepatitis A, seasonal influenza, and hand, foot, and mouth disease. Based in Beijing, the company operates high-capacity GMP-certified facilities and maintains extensive global distribution partnerships to support public health immunization programs.